心鈉肽(ANP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Atrial Natriuretic Peptide (ANP)
ANH; ANF; CDD; Atrial Natriuretic Factor; Atrial Natriuretic Hormone; Atriopeptin; Cardionatrine; Cardiodilatin
- 編號(hào)CEA225Si
- 物種Rhesus monkey (Simian，恒河猴)相同的名稱(chēng)，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)2h
- 檢測(cè)范圍12.35-1,000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于5.35pg/mL.
- 樣本類(lèi)型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格48T96T96T*596T*1096T*100
- 價(jià)格¥ 3402¥ 4860¥ 21870¥ 41310¥ 340200
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實(shí)驗(yàn)結(jié)果圖
標(biāo)準(zhǔn)曲線(xiàn)圖
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)心鈉肽(ANP)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的心鈉肽(ANP)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 84-96 | 89 |
| EDTA plasma(n=5) | 98-105 | 101 |
| heparin plasma(n=5) | 85-99 | 93 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線(xiàn)性
在定值血清及血漿樣本內(nèi)加入適量的心鈉肽(ANP)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線(xiàn)性范圍即為稀釋后樣本中心鈉肽(ANP)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 78-99% | 88-96% | 89-97% | 83-97% |
| EDTA plasma(n=5) | 78-98% | 91-101% | 96-105% | 78-95% |
| heparin plasma(n=5) | 81-105% | 97-104% | 85-96% | 79-95% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）50µL，
加入50µL檢測(cè)液A(臨用前配制);
37°C溫育1小時(shí)。
3. 洗板3次；
4. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
5. 洗板5次；
6. 加TMB底物90µL，37°C孵育10-20分鐘；
7. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
本試劑盒應(yīng)用競(jìng)爭(zhēng)抑制酶聯(lián)免疫分析法測(cè)定標(biāo)本中待測(cè)物質(zhì)水平。將心鈉肽(ANP)單克隆抗體包被微孔板，制成固相載體，往包被抗體的微孔中同時(shí)加入生物素標(biāo)記的抗原和待測(cè)抗原(標(biāo)準(zhǔn)品或樣本)，待測(cè)抗原與生物素標(biāo)記抗原對(duì)特異性抗體進(jìn)行競(jìng)爭(zhēng)結(jié)合。溫育后經(jīng)洗滌去掉未結(jié)合物，然后加入HRP標(biāo)記的親和素，經(jīng)過(guò)溫育和徹底洗滌后加入底物TMB顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。待測(cè)標(biāo)本濃度越高，標(biāo)記抗原和抗體的結(jié)合就越受到抑制，顯色愈淺。顯色的深淺與酶量呈正相關(guān)，而與樣品中待測(cè)物質(zhì)含量呈負(fù)相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度（O.D.值），計(jì)算樣品濃度。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rhesus monkey (Simian，恒河猴) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| CEA225Si | 心鈉肽(ANP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA225Si | 心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| 8 | Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular Function[PubMed: 21616283] |
| Basic Research in Cardiology | Release of atrial natriuretic peptide precedes shedding of the endothelial glycocalyx equally in patients undergoing on- and off-pump coronary artery bypass surgery[PubMed: 21769675] |
| Neuropsychobiology. | Atrial natriuretic Peptide, arginine vasopressin Peptide and cortisol serum levels in opiate-dependent patients[PubMed: 23406607] |
| European addiction research | Alcohol-induced changes in methylation status of individual CpG sites, and serum levels of vasopressin and atrial natriuretic peptide in alcohol-dependent patients during detoxification treatment.[Pubmed: 24356727] |
| Crit Care. | Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx[Pubmed:25497357] |
| Diabet Med.? | Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes.[Pubmed:26927445] |
| J Ethnopharmacol | Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by reCavia (Guinea pig )lating p38 and NF-κb pathway[Pubmed:26970569] |
| Journal of Babylon University/Pure and Applied Sciences | Blood Pressure and Atrial Natriuretic Peptide (ANP) Levels in Patients with Autosomal Dominant Polycystic Kidney Disease.[papers:uobj_paper_2016_62613672.pdf] |
| PLoS One | Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy[pubmed:29240788] |
| Drug Delivery | Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy.[pubmed:29063791] |
| Elife | SIRT2 deacetylase regulates the activity of GSK3 isoforms independent of inhibitory phosphorylation[Pubmed:29504933] |
| Science?of the?Total?Environment | Co-exposure of silica nanoparticles and methylmercury induced cardiac toxicity and[Pubmed:29727991] |
| The Journal of Biological Chemistry | Toll-like receptor 2 deficiency hyperactivates the FoxO1 transcription factor and induces aging-associated cardiac dysfunction in mice[Pubmed:29929978] |
| Pediatric Cardiology | Determinants of Increased Aortic Diameters in Young Normotensive Patients With Turner Syndrome Without Structural Heart Disease[Pubmed:29392348] |
| FASEB?Journal | Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure[Pubmed: 30230922] |
| Endokrynologia Polska | Endothelin-1 (ET-1), N-terminal fragment of proatrial natriuretic peptide (NTpro-ANP) and tumor necrosis factor alpha (TNF-α) in children with primary hypertension?…[Pubmed: 30359461] |
| International Journal of Peptide Research and Therapeutics | ANP/NPRA Inhibits Epithelial-Mesenchymal Transition of Airway by Targeting Smad3 in Asthma[] |
| Van Veterinary Journal | Relationship between Natriuretic Peptide Levels with Heart and Kidney Parameters in Rats with Chronic Renal Failure.[] |
| Acta Pharmaceutica Sinica B | The poly (ADP-ribosyl) ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy[34094834] |
| Peptides | Alarin moderated myocardial hypertrophy via inhibiting cyclic adenosine monophosphate/protein kinase A signaling pathway to attenuate autophagy[34624429] |
| Peptides | Osteocrin alleviates cardiac hypertrophy via attenuating oxidative stress[Pubmed:35218795] |
